Scholarlink

Background <p>Autoimmune diseases (AID) have been showed to be susceptibility to malignancy. This study aimed to analyzed the profile of serum tumor markers in four common autoimmune disease.</p> Methods <p>Patients with dermatomyositis (DM, <i>n</i> = 132), Systemic sclerosis (SSc, <i>n</i> = 77), Systemic lupus erythematosus (SLE, <i>n</i> = 191), Rheumatoid arthritis (RA, <i>n</i> = 160) and ovarian cancer (<i>n</i> = 250) were included in this study. Twelve tumor markers (CA724, AFP, FRT, NSE, CA19-9, CA125, CYFRA21-1, CA153, <i>β</i>-HCG and HE4) levels and abnormal rate in these patients were retrospective statistics. The tumor markers profiles were compared among the different AID.</p> Results <p>Compared with ovarian cancer (OV) patients, there were no significant differences for the levels and abnormal rates of CYFRA21-1/HE4/CA50/FRT in AID patients. The levels and abnormal rates of CA724/FRT/CA125/NSE were higher in OV patients than that in AID patients. 75% AID patients have at least one elevated tumor marker. 69.46% AID patients have 2–5 elevated tumor markers. All the 12 tumor markers were negative in 16.67, 19.74, 27.23 and 32.70% of DM, SSc, SLE and RA patients. Except CA50, the levels of the other eleven tumor markers were significantly different between DM/SSc/SLE/RA. Except AFP/β-HCG/SCC, the abnormal rate of the other tumor markers were significantly different between these AID.</p> Conclusions <p>The increased levels of tumor makers were common in four major AID, and the profile of tumor makers were significantly different among these AID.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tumor markers level profile in dermatomyositis, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月14日

查看全文
  • Jin-chi Cai,
  • Lan Yang,
  • Ying-sen Xue,
  • Song-bo Wang,
  • Li Zhang,
  • Ke-nan Duan,
  • Zhao-wei Gao,
  • Jun Li

摘要

Background

Autoimmune diseases (AID) have been showed to be susceptibility to malignancy. This study aimed to analyzed the profile of serum tumor markers in four common autoimmune disease.

Methods

Patients with dermatomyositis (DM, n = 132), Systemic sclerosis (SSc, n = 77), Systemic lupus erythematosus (SLE, n = 191), Rheumatoid arthritis (RA, n = 160) and ovarian cancer (n = 250) were included in this study. Twelve tumor markers (CA724, AFP, FRT, NSE, CA19-9, CA125, CYFRA21-1, CA153, β-HCG and HE4) levels and abnormal rate in these patients were retrospective statistics. The tumor markers profiles were compared among the different AID.

Results

Compared with ovarian cancer (OV) patients, there were no significant differences for the levels and abnormal rates of CYFRA21-1/HE4/CA50/FRT in AID patients. The levels and abnormal rates of CA724/FRT/CA125/NSE were higher in OV patients than that in AID patients. 75% AID patients have at least one elevated tumor marker. 69.46% AID patients have 2–5 elevated tumor markers. All the 12 tumor markers were negative in 16.67, 19.74, 27.23 and 32.70% of DM, SSc, SLE and RA patients. Except CA50, the levels of the other eleven tumor markers were significantly different between DM/SSc/SLE/RA. Except AFP/β-HCG/SCC, the abnormal rate of the other tumor markers were significantly different between these AID.

Conclusions

The increased levels of tumor makers were common in four major AID, and the profile of tumor makers were significantly different among these AID.